CO-TEKNOWLEDGE
9.4.2024 14:01:32 CEST | Business Wire | Press release
TeKnowledge marks its global debut today, bringing together the formidable strengths of Cytek Security, Tek Experts, and Elev8 into a single, unified powerhouse. Each entity contributes its specialized expertise—Cytek Security in cutting-edge cybersecurity readiness, Tek Experts in unparalleled enterprise technical managed services, and Elev8 in innovative technical skilling—creating a comprehensive portfolio under TeKnowledge that offers end-to-end digital transformation services. This strategic amalgamation heralds the beginning of a new era in tech services, where TeKnowledge stands as the transformative catalyst for digital evolution, providing governments and enterprises worldwide with unparalleled cybersecurity services, advanced technical skilling, and enterprise technical managed services at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409688971/en/
TeKnowledge: Uniting Cytek Security, Tek Experts, and Elev8 under one banner to pioneer the future of secure digital transformation and tech talent empowerment across the globe (Graphic: Business Wire)
Backed by over a decade of pioneering achievements in the tech services industry and a distinguished roster of government and enterprise customers worldwide, TeKnowledge is uniquely equipped to navigate the complexities of digital modernization. By integrating these powerhouse brands, TeKnowledge tackles the critical challenges of bridging the tech talent gap and expediting digital imperatives, providing a holistic suite of services tailored to bolster cybersecurity defenses, cultivate essential technical skills, and deliver expert technical managed services to streamline and accelerate digital strategies.
Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services. Drawing upon her notable success at various tech giants including Microsoft and HP, Aileen has swiftly positioned TeKnowledge as a leader in secure and scalable technology solutions. In her first strategic initiative, Aileen has built an exceptional leadership team, merging seasoned executives from Tek Experts, Elev8, and Cytek, and enriched by strategic new appointments. This includes bringing on board Jyllene Miller as Chief Revenue and Growth Officer, tapping into her extensive experience in growth strategies and market development garnered at numerous Fortune 500 companies to propel TeKnowledge's global expansion. The team is further bolstered by Eric Schifflers as Chief Information Security Officer (CISO), whose vast experience across global organizations like NATO, Ria Money Transfer, and Roche, amplifies TeKnowledge's cybersecurity defenses and strategic security initiatives.
The executive leadership team at TeKnowledge, a dynamic group of seasoned leaders, embodies a wealth of diverse expertise, driving the company's strategic vision across public and private sectors. Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities. This team's unified approach is setting new industry standards, establishing TeKnowledge as a leader in digital services and a catalyst for transformative growth and resilience in the digital era.
"A unified TeKnowledge signifies a major shift in digital transformation services," states Aileen Allkins, President and CEO. "Bringing together the expertise of Cytek Security, Tek Experts, and Elev8 under the TeKnowledge umbrella, creates a synergy that benefits our customers as we enhance our delivery, achieving faster, more impactful outcomes. This positions us to effectively tackle the tech talent gap and pace of digital innovation. Offering a comprehensive suite of elite cybersecurity services, top-tier digital skilling, and scalable technical managed services, TeKnowledge is committed to guiding governments and enterprises worldwide through the complexities of digital transformation. Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."
How TeKnowledge is Bridging Global Divides with Local Impact:
- Optimized Managed Technical Services: TeKnowledge (f.k.a. Tek Experts) stands out with its superior operational excellence and agile solutions, supported by a global network of professionals, including a significant presence in emerging markets. Our enterprise managed services are distinguished by their ability to seamlessly integrate and scale, ensuring organizations achieve operational superiority and strategic success in the digital landscape.
- Precision Technical Skilling: Directly addressing the global talent gap, TeKnowledge's (f.k.a. Elev8) custom training programs are strategically designed to equip both the current and future generations with the skills needed to navigate and excel in the ever-evolving tech landscape, preparing them for the challenges and opportunities that lie ahead.
-
Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a. Cytek Security) equips customers with dynamic defenses against the evolving cyber landscape.
The launch of TeKnowledge heralds an important evolution in the global digital landscape, emphasizing a future where digital security and operational excellence transform from aspirations into baseline expectations worldwide. At the core of this transformation is the robust talent—engineers supporting engineers, and developers supporting developers—to ensure unparalleled expertise and collaboration in tackling the digital challenges ahead.
To learn more about TeKnowledge, visit www.TeKnowledge.com.
About TeKnowledge: Accelerating Progress, Securing Futures.
TeKnowledge stands as the transformative catalyst for digital evolution, enabling governments and enterprises worldwide to navigate the challenges with digital transformation today and tomorrow with elite cybersecurity implementation and managed security services (MSS), top-tier digital skilling, and technical managed services at scale. TeKnowledge envisions a world where every government and enterprise is empowered with the most advanced, secure, and accessible technology solutions. Our commitment to technology enablement, security, and advancement positions us uniquely in the market, ensuring our customers are equipped to achieve their strategic imperatives in the digital age with confidence and competitive advantage. Start your journey towards digital excellence by visiting TeKnowledge.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409688971/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
